Standard Biotools (LAB) Cash from Investing Activities Growth (1y) (2011 - 2026)
Standard Biotools (LAB) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.93 Bn | 193.33 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 128.56 Bn | 125.08 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 119.26 Bn | 110.04 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 52.06 Bn | 47.81 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.55 Bn | 32.61 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 34.05 Bn | 31.94 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.39 Bn | 23.07 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.15 Bn | 22.67 Bn | 684.20 Mn | 0.00% |
| 10 | Standard Biotools | 254.39 Mn | -222.33 Mn | 10.54 Mn | -47.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.62% |
| Mar 31, 2026 | 1,206.60% |
| Dec 31, 2025 | -131.25% |
| Sep 30, 2025 | 78.37% |
| Jun 30, 2025 | -45.27% |
| Mar 31, 2025 | -95.40% |
| Dec 31, 2024 | 296.13% |
| Sep 30, 2024 | 38.14% |
| Jun 30, 2024 | 25.25% |
| Mar 31, 2024 | 637.07% |
| Dec 31, 2023 | -132.59% |
| Sep 30, 2023 | -565.03% |
| Jun 30, 2023 | 129.03% |
| Mar 31, 2023 | 5,071.66% |
| Sep 30, 2022 | 199.40% |
| Jun 30, 2022 | -1,419.96% |
| Mar 31, 2022 | 82.37% |
| Sep 30, 2021 | -181.76% |
| Jun 30, 2021 | -189.82% |
| Mar 31, 2021 | -128.20% |